---
document_datetime: 2024-07-22 13:40:08
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/byannli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: byannli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7890981
conversion_datetime: 2025-12-22 12:29:07.298285
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BYANNLI

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0006               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 19/07/2024                          |                                             | PL                               |           |
| II/0005              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   | 01/02/2024                          | n/a                                         |                                  |           |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| WS/2405            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                               | 25/05/2023   | 25/04/2024   | SmPC, Labelling and PL   |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------|
| PSUSA/2266/ 202106 | Periodic Safety Update EU Single assessment - paliperidone                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/02/2022   | n/a          |                          | PRAC Recommendation - maintenance |
| X/0002/G           | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs C.I.7.b - Deletion of - a strength C.I.7.b - Deletion of - a strength C.I.7.b - Deletion of - a strength C.I.7.b - Deletion of - a strength C.I.7.b - Deletion of - a strength C.I.7.b - Deletion of - a strength A.7 - Administrative change - Deletion of manufacturing sites | 16/09/2021   | 22/11/2021   | SmPC, Labelling and PL   |                                   |
| WS/1877            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                    | 09/04/2021   | 22/11/2021   | SmPC and PL              |                                   |

<div style=\"page-break-after: always\"></div>

| data   |
|--------|